Takeda Pharmaceutical (TAK) Competitors

Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, community ranking, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Which has higher earnings & valuation, SNY or TAK?

Sanofi has higher earnings, but lower revenue than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$45.17B	2.76	$6.02B	$2.80	18.15
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.22	69.95

Is SNY or TAK more profitable?

Sanofi has a net margin of 12.77% compared to Takeda Pharmaceutical's net margin of 4.53%. Sanofi's return on equity of 25.61% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	12.77%	25.61%	14.72%
Takeda Pharmaceutical	4.53%	9.39%	4.53%

Is SNY or TAK a better dividend stock?

Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.1%. Takeda Pharmaceutical pays an annual dividend of $0.26 per share and has a dividend yield of 1.7%. Sanofi pays out 57.1% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 118.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Do analysts prefer SNY or TAK?

Sanofi presently has a consensus price target of $61.50, suggesting a potential upside of 20.99%. Given Sanofi's stronger consensus rating and higher possible upside, research analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	3 Strong Buy rating(s)	3.13
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals & insiders hold more shares of SNY or TAK?

14.0% of Sanofi shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has more volatility and risk, SNY or TAK?

Sanofi has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500.

Does the MarketBeat Community favor SNY or TAK?

Takeda Pharmaceutical received 48 more outperform votes than Sanofi when rated by MarketBeat users. However, 60.92% of users gave Sanofi an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Sanofi	Outperform Votes 53 60.92%	Underperform Votes 34 39.08%
Takeda Pharmaceutical	Outperform Votes 101 57.06%	Underperform Votes 76 42.94%

Does the media favor SNY or TAK?

In the previous week, Sanofi had 21 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 23 mentions for Sanofi and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.00 beat Sanofi's score of 0.87 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	12 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sanofi beats Takeda Pharmaceutical on 17 of the 21 factors compared between the two stocks.